Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Syncytial Virus Clear all

Conditions: Respiratory Syncytial Virus Prevention
Interventions: Ad26.RSV.PreF-based Vaccine; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA-BN-RSV vaccine, Tris Buffered Saline (TBS); Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 60 Years and older
Enrollment: 20,419 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 105
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSV-F Vaccine, Phosphate Buffer Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 1,330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Healthy
Interventions: SARS-CoV-2/Influenza/RSV RT-PCR; Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 9,151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Respiratory Syncytial Virus Infections
Interventions: D46/NS2/N/ΔM2-2-HindIII, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: ALN-RSV01; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions: N95 Respirator, Medical/surgical mask; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,862 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 7
States / cities: Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Presatovir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: RSV Infection
Interventions: Candidate vaccine, SCB-1019T, AREXVY, placebo; Biological · Other
Lead sponsor: Clover Biopharmaceuticals USA, LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 10,994 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 109
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more

Conditions: Respiratory Tract Infections
Interventions: Respiratory pathogen panel PCR test, COVID-19 antibody test; Diagnostic Test
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Respiratory Syncytial Virus Hospitalizations
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Up to 12 Months
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 44
States / cities: Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 40 more

Conditions: RSV Infection
Interventions: Obeldesivir, Obeldesivir Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 121
States / cities: Birmingham, Alabama • Cullman, Alabama • Guntersville, Alabama + 81 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Up to 6 Months
Enrollment: 1,177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 107
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: MEDI8897, Palivizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 1 Year
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 27 more

Conditions: RSV Infection
Interventions: Obeldesivir, Obeldesivir Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 5 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more

Conditions: Healthy
Interventions: IVX-A12, Placebo; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more

Conditions: Acute Respiratory Infection
Interventions: Nasal Swab Sample; Diagnostic Test
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Guntersville, Alabama • Mesa, Arizona + 30 more

Conditions: Healthy Participants
Interventions: IVX-A12, Licensed RSV Vaccine; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more

Conditions: RSV Infection
Interventions: EDP-938, Cyclosporine, Prednisone; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Respiratory Syncytial Virus
Interventions: Nasal swab sampling, Blood sampling, Diary cards; Procedure · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 6 Years
Enrollment: 2,409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 9
States / cities: Oakland, California • Sacramento, California • Santa Clara, California + 5 more

Conditions: -Unhealthy Children With a History of Prematurity
Interventions: MEDI-493; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Months to 6 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

MVA-BN-RSV Vaccine Trial

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

The Respiratory Protection Effectiveness Clinical Trial

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

A Study of Acute Respiratory Infections in Global Outpatient Setting

A Study of IVX-A12 in Adults Participants

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)